The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | Preliminary data from the MANIFEST study: pelabresib in combination with ruxolitinib in MF
Prithviraj Bose, MBBS, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses preliminary findings from the MANIFEST study (NCT02158858), which is evaluating the safety and efficacy of pelabresib in combination with ruxolitinib in patients with myelofibrosis (MF). Dr Bose comments on the encouraging results observed in arms two and three of this study, including the reduction in spleen volume in patients, as well as the improvement in bone marrow fibrosis.This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
